Improving patient access to life-enhancing medications

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals.

We have a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world.

More about us Our capabilities
Female stretching

We offer patients better, safer & more accessible medicines.

View our products Explore our capabilities
Man looking in microscope

Capabilities

To improve patient access to life-enhancing prescription medications, Mayne Pharma offers a robust portfolio of branded and generic drugs in multiple therapeutic areas, including women's health, oncology, dermatology and cardiology.

Learn more
Pills

Contract services

Mayne Pharma has two full-service contract development and manufacturing organisations (CDMO) specialising in novel oral and topical dose forms providing pharmaceutical development, analytical testing and commercial manufacturing to over 100 clients worldwide. Our mission is to partner with clients to develop and deliver pharmaceutical products from “concept to commercialisation” to change the lives of patients around the globe:

Learn more

Sustainability

At Mayne Pharma, we recognise that we are part of a global community. As part of this community, we are committed to operating our business in a sustainable manner. We ensure our people are safe and well-supported, local communities prosper and the environment is well cared for so that it benefits future generations.

Learn more

For investors

More for investors

ASX: - AEST

  • Open
  • High
  • Low
  • Market Cap
  • Volume
  • 52 week

News & Events

View all

Greenville high res copy

Mayne Pharma announces sale of Metrics Contract Services

10 Aug 2022

Mayne Pharma today announced that it has entered into an agreement with Catalent to sell Metrics Contract Services for a total cash consideration of US$475 million (~A$679 million)

Learn more

Hands holding a Nuvaring

Mayne Pharma and Mithra announce FDA approval of Haloette, a generic version of Nuvaring

8 Aug 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) vaginal hormonal contraceptive ring

Learn more

Prix_Galien_USA_2022-larger

NEXTSTELLIS® oral contraceptive nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent

2 Aug 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent.

Learn more

Nextstellis_2021_Marketing-28 (1)

Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS®

29 Jul 2022

Mayne Pharma Group Limited is pleased to announce a new strategic collaboration with GoodRx, a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.

Learn more

Contraceptive Packet

NEXTSTELLIS® oral contraceptive now available in Australia

26 Jul 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets), a first-of-its kind oral contraceptive with a novel estrogen is now available in Australia.

Learn more

Aaron Gray, CFO

New Chief Financial Officer appointment

22 Jul 2022

Mayne Pharma Group Limited is pleased to announce that Mr Aaron Gray has been appointed as Chief Financial Officer (CFO), effective 29 August 2022.

Learn more